US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by SpringWorks Therapeutics, Inc.
< Previous
1
2
Next >
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
March 02, 2026
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
October 21, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
August 18, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
July 18, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
April 28, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
April 27, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
February 20, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
January 30, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
November 11, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
November 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
August 28, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
July 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
< Previous
1
2
Next >
